BACKGROUND: Most studies with corticotropin releasing factor (CRF) and ethanol (EtOH) consumption have focused on CRF type 1 (CRF1 ) receptors; less is known about other components of the CRF system, such as the CRF type 2 (CRF2 ) receptors and the CRF binding protein (CRFBP). In humans, several nucleotide polymorphisms in the CRFBP gene have been associated with EtOH abuse. METHODS: The role of the CRFBP within the ventral tegmental area (VTA) and the central nucleus of the amygdala (CeA) was investigated in C57BL/6J mice exposed to an EtOH binge drinking paradigm (drinking in the dark [DID]), or to a dependence-producing drinking protocol (2-bottle choice, intermittent access to alcohol [IAA]) for 4 weeks. Potential interactions between VTA CRFBP and CRF2 receptors on EtOH binge drinking were also assessed. Mice were microinjected with the CRFBP antagonist CRF fragment 6-33 (CRF6-33 ) into the VTA or CeA, or with the CRF2 antagonist astressin-2B (A2B) alone or in combination with CRF6-33 into the VTA, and had access to 20% (w/v) EtOH for 4 hours (DID). Separate cohorts of mice received vehicle and doses of CRF6-33 into the VTA or CeA and had access to EtOH/water for 24 hours (IAA). Blood EtOH concentrations (BECs) were measured, and signs of withdrawal by handling-induced convulsions were determined. RESULTS: Intra-VTA CRF6-33 and A2B reduced EtOH intake dose dependently in mice during DID. Furthermore, a combination of a subeffective dose of CRF6-33 and a lower dose of A2B promoted additive effects in attenuating EtOH binge drinking. Intra-VTA CRF6-33 did not affect EtOH consumption in mice given IAA, and intra-CeA CRF6-33 did not change alcohol consumption in both models of drinking. DID and IAA promoted pharmacologically relevant BECs; however, only mice given IAA exhibited convulsive events during withdrawal. CONCLUSIONS: These findings suggest that VTA CRFBP is involved in the initial stages of escalated EtOH drinking by mechanisms that may involve CRF2 receptors.
BACKGROUND: Most studies with corticotropin releasing factor (CRF) and ethanol (EtOH) consumption have focused on CRF type 1 (CRF1 ) receptors; less is known about other components of the CRF system, such as the CRF type 2 (CRF2 ) receptors and the CRF binding protein (CRFBP). In humans, several nucleotide polymorphisms in the CRFBP gene have been associated with EtOH abuse. METHODS: The role of the CRFBP within the ventral tegmental area (VTA) and the central nucleus of the amygdala (CeA) was investigated in C57BL/6J mice exposed to an EtOH binge drinking paradigm (drinking in the dark [DID]), or to a dependence-producing drinking protocol (2-bottle choice, intermittent access to alcohol [IAA]) for 4 weeks. Potential interactions between VTA CRFBP and CRF2 receptors on EtOH binge drinking were also assessed. Mice were microinjected with the CRFBP antagonist CRF fragment 6-33 (CRF6-33 ) into the VTA or CeA, or with the CRF2 antagonist astressin-2B (A2B) alone or in combination with CRF6-33 into the VTA, and had access to 20% (w/v) EtOH for 4 hours (DID). Separate cohorts of mice received vehicle and doses of CRF6-33 into the VTA or CeA and had access to EtOH/water for 24 hours (IAA). Blood EtOH concentrations (BECs) were measured, and signs of withdrawal by handling-induced convulsions were determined. RESULTS: Intra-VTA CRF6-33 and A2B reduced EtOH intake dose dependently in mice during DID. Furthermore, a combination of a subeffective dose of CRF6-33 and a lower dose of A2B promoted additive effects in attenuating EtOH binge drinking. Intra-VTA CRF6-33 did not affect EtOH consumption in mice given IAA, and intra-CeACRF6-33 did not change alcohol consumption in both models of drinking. DID and IAA promoted pharmacologically relevant BECs; however, only mice given IAA exhibited convulsive events during withdrawal. CONCLUSIONS: These findings suggest that VTA CRFBP is involved in the initial stages of escalated EtOH drinking by mechanisms that may involve CRF2 receptors.
Authors: Lara S Hwa; Adam Chu; Sally A Levinson; Tala M Kayyali; Joseph F DeBold; Klaus A Miczek Journal: Alcohol Clin Exp Res Date: 2011-06-01 Impact factor: 3.455
Authors: Emily G Lowery-Gionta; Montserrat Navarro; Chia Li; Kristen E Pleil; Jennifer A Rinker; Benjamin R Cox; Gretchen M Sprow; Thomas L Kash; Todd E Thiele Journal: J Neurosci Date: 2012-03-07 Impact factor: 6.167
Authors: Marisa Roberto; Maureen T Cruz; Nicholas W Gilpin; Valentina Sabino; Paul Schweitzer; Michal Bajo; Pietro Cottone; Samuel G Madamba; David G Stouffer; Eric P Zorrilla; George F Koob; George R Siggins; Loren H Parsons Journal: Biol Psychiatry Date: 2010-01-08 Impact factor: 13.382
Authors: Verginia C Cuzon Carlson; Gail K Seabold; Christa M Helms; Natasha Garg; Misa Odagiri; Andrew R Rau; James Daunais; Veronica A Alvarez; David M Lovinger; Kathleen A Grant Journal: Neuropsychopharmacology Date: 2011-07-27 Impact factor: 7.853
Authors: Mary-Anne Enoch; Pei-Hong Shen; Francesca Ducci; Qiaoping Yuan; Jixia Liu; Kenneth V White; Bernard Albaugh; Colin A Hodgkinson; David Goldman Journal: PLoS One Date: 2008-10-31 Impact factor: 3.240
Authors: Kevin P Uribe; Victor L Correa; Briana E Pinales; Rodolfo J Flores; Bryan Cruz; Zhiying Shan; Adriaan W Bruijnzeel; Arshad M Khan; Laura E O'Dell Journal: Neuropsychopharmacology Date: 2019-10-15 Impact factor: 7.853
Authors: Jennifer A Rinker; S Alex Marshall; Christopher M Mazzone; Emily G Lowery-Gionta; Varun Gulati; Kristen E Pleil; Thomas L Kash; Montserrat Navarro; Todd E Thiele Journal: Biol Psychiatry Date: 2016-03-03 Impact factor: 13.382